2 years ago
APLS
Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
---|---|---|---|---|---|
Iveric Bio IncISEE | +150.13% | $14.94 | $37.37 | 2022-09-06 - 2023-05-04 | Buy |
Ocular Therapeutix IncOCUL | +149.31% | $3.61 | $9.00 | 2023-09-13 - 2024-09-13 | Buy |
Surface Oncology IncSURF | +85.12% | $0.58 | $1.07 | 2023-05-03 - 2023-09-07 | Buy |
Oculis Holding AgOCS | +66.02% | $11.92 | $19.79 | 2024-06-10 - 2025-06-10 | Buy |
Apellis Pharmaceuticals IncAPLS | +63.50% | $24.22 | $39.60 | 2023-07-31 - 2024-07-31 | Buy |
Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
---|---|---|---|---|---|---|
Nuvalent IncNUVL | 2 | Buy | $112.00 | +39.17% | Maintains | 9 days ago |
Enliven Therapeutics IncELVN | 3 | Buy | $52.00 | +150.84% | Maintains | 18 days ago |
Agenus IncAGEN | 4 | Hold | $6.00 | -1.15% | Maintains | a month ago |
Apellis Pharmaceuticals IncAPLS | 11 | Buy | $47.00 | +157.39% | Maintains | 2 months ago |
Oculis Holding AgOCS | 4 | Buy | $41.00 | +115.79% | Maintains | 4 months ago |
Coherus Biosciences IncCHRS | 5 | Buy | $6.00 | +640.74% | Maintains | 7 months ago |
Spyre Therapeutics IncSYRE | 2 | Buy | $65.00 | +312.44% | Maintains | 8 months ago |
Mersana Therapeutics IncMRSN | 4 | Hold | $3.00 | +938.06% | Maintains | a year ago |
Ocular Therapeutix IncOCUL | 4 | Buy | $17.00 | +76.72% | Maintains | a year ago |
Oric Pharmaceuticals IncORIC | 1 | Buy | $25.00 | N/A | Reiterates | a year ago |
Surface Oncology IncSURF | 5 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Iveric Bio IncISEE | 3 | Hold | $40.00 | N/A | Downgrades | 2 years ago |
Harpoon Therapeutics IncHARP | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Aveo Pharmaceuticals IncAVEO | 1 | Hold | $15.00 | N/A | Downgrades | 3 years ago |
Karyopharm Therapeutics IncKPTI | 1 | Buy | $210.00 | N/A | Maintains | 3 years ago |
Iovance Biotherapeutics IncIOVA | 2 | Buy | $34.00 | N/A | Maintains | 3 years ago |
Sab Biotherapeutics IncSABS | 1 | Buy | $230.00 | N/A | Initiates Coverage On | 4 years ago |